GGrantIndex
← Leaderboards

Wassana Yantasee

Battelle Pacific Northwest Laboratories

Google Scholar ↗PubMed ↗ORCID ↗
$6,660,616
Attributed
$11,914,449
Total exposure
11
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.3M · FY2006–25
$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,717,425 · 10
CDC$197,024 · 1

By mechanism

R44$8,578,298 · 4
R01$1,785,202 · 1
R21$676,208 · 3
R43$325,000 · 1
R41$299,741 · 1
SB1$250,000 · 1

Top collaborators

Most similar at Battelle Pacific Northwest Laboratories

Same institution · by research overlap

Others in their field

Top investigators on “Dose”

Research focus

DoseLeadNanoparticleCellsIn VivoSafetyCell DeathCancer CellMalignant NeoplasmsSilicon DioxideSmall Business Innovation Research GrantUptakeToxic EffectSuccessTumorCollaborationsCessation Of LifeBaseSpecificityImmuneMouse ModelPharmaceutical PreparationsAntibodiesParticle Size

Grant awards (24)

PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$1,288,251
R44 · FY2025 · CA
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$89,348
SB1 · FY2025 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2024 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$914,249
R44 · FY2024 · CA
Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment$160,652
SB1 · FY2024 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$932,751
R44 · FY2023 · CA
PLK1 and EGFR targeted nanoconstruct as a monotherapy and a radiation sensitizer for lung cancer$400,000
R44 · FY2023 · CA
ROS-induced SPIO Targeted Platform for Transarterial Liver Cancer Therapy$211,665
R21 · FY2022 · CA
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$101,639
R44 · FY2022 · CA
In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response$1,898,361
R44 · FY2021 · CA
Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer$378,030
R44 · FY2021 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$513,354
R44 · FY2019 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$233,858
R44 · FY2019 · CA
Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$14,938
R44 · FY2019 · CA
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$745,151
R44 · FY2018 · CA
Development of topical formulation of siRNA-nanoparticle for treating skin diseases$325,000
R43 · FY2017 · TR
Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer$224,965
R44 · FY2017 · CA
Nephrogenic Systemic Fibrosis (NSF): A Rodent Model for Therapeutic Intervention$439,619
R01 · FY2013 · GM · contact PI
Nephrogenic Systemic Fibrosis (NSF): A Rodent Model for Therapeutic Intervention$452,438
R01 · FY2012 · GM · contact PI
Iron functionalized silica as oral phosphate binder to treat hyperphosphatemia$299,741
R41 · FY2012 · DK · contact PI
Nephrogenic Systemic Fibrosis (NSF): A Rodent Model for Therapeutic Intervention$452,085
R01 · FY2011 · GM · contact PI
Nephrogenic Systemic Fibrosis (NSF): A Rodent Model for Therapeutic Intervention$441,060
R01 · FY2010 · GM · contact PI
Novel Chelators for Highly Efficient Removal of Toxic Heavy Metals in Humans$267,519
R21 · FY2008 · ES · contact PI
Portable Analyzer for On-site Monitoring of Worker Exposure to Toxic Metals$197,024
R21 · FY2006 · OH · contact PI